[Similar efficacy of less than 6 and 7-10 courses of therapy with anthracycline-based combination chemotherapy for localized non-Hodgkin's lymphoma of extranodal type].
We studied retrospectively the influence on the prognosis of patients with localized non-Hodgkin's lymphoma of extranodal type with regard to the duration of an anthracycline-based combination chemotherapy-modified CHOP regimen. The patients who were given at least 2 courses of chemotherapy and attained complete remission were selected. These were subdivided into two groups; one for patients who were given 2-6 courses, the other for patients given 7-10 courses. The relapse-free survival curve for patients treated with 7-10 courses was slightly better than that of the patients treated with less than 6 courses. However, the difference between them was not significant. From the results, it was considered possible to reduce the chemotherapy from 10 to 6 courses in patients with localized non-Hodgkin's lymphoma of extranodal type. A prospective randomized study is now in progress at Saitama Cancer Center.
Sampi
K
K
Hematology Clinic Saitama Cancer Center, Japan.
Takouda
K
K
Takagi
T
T
Hattori
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone